Oncotelic Therapeutics Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency.

The editorial notes that Oncotelic is advancing its Sapu003 program and Deciparticle platform as part of a broader trend toward nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy focuses on developing platform technologies with potential applications across multiple oncology and rare disease indications rather than relying on a single therapeutic candidate. To view the full press release, visit https://ibn.fm/hwkoB.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics. For more information, visit the company’s newsroom at https://ibn.fm/OTLC.